NovLeuReg
Identification and characterization of novel essential regulators of acute myeloid leukemia
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0NovLeuReg project word cloud
Explore the words cloud of the NovLeuReg project. It provides you a very rough idea of what is the project "NovLeuReg" about.
Project "NovLeuReg" data sheet
The following table provides information about the project.
| Coordinator |
KOBENHAVNS UNIVERSITET
Organization address contact info |
| Coordinator Country | Denmark [DK] |
| Project website | https://www.bric.ku.dk/research/helin_group/ |
| Total cost | 212˙194 € |
| EC max contribution | 212˙194 € (100%) |
| Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
| Code Call | H2020-MSCA-IF-2014 |
| Funding Scheme | MSCA-IF-EF-ST |
| Starting year | 2016 |
| Duration (year-month-day) | from 2016-04-01 to 2018-09-02 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | KOBENHAVNS UNIVERSITET | DK (KOBENHAVN) | coordinator | 212˙194.00 |
Map
Project objective
Acute myeloid leukemia is a hematopoietic malignancy characterized by the abnormal proliferation of immature myeloid cells. The implementation of high-throughput sequencing revealed that somatic mutations in various epigenetic regulators represent a frequent pathogenic phenomenon in leukemogenesis. This raised optimism for the development of new therapies in leukemia due to the reversible nature of epigenetic marks and amenability of chromatin-modifying enzymes to pharmacological inhibition. However, realization of this potential requires further research into epigenetic mechanisms governing the maintenance of leukemic cells. The overall goal of the proposed work is to characterize novel important epigenetic regulators in leukemic cells and to assess their potential as drug targets. Firstly, I plan to identify and study epigenetic regulators essential for leukemic cells deficient in TET2, an enzyme that hydroxylates methylated cytosines in DNA. This will be achieved by performing state-of-the-art shRNA screens in mouse Tet2-null leukemia models and by exploring the functions of the uncovered candidates using a range of cell biology, biochemistry, and functional genomics approaches. The second aim is to investigate the molecular functions of SETD5, a newly-uncovered epigenetic regulator of leukemic cells. This will be achieved by identifying its target genes and interacting partners in leukemic cells and by exploring the effects of its depletion on normal and cancer cells. The accomplishment of both research aims will provide new insights into epigenetic regulation of leukemic cells and highlight novel drug targets for future therapy development. The project will be supervised by Prof Kristian Helin, a world-leading expert in the field of epigenetics and cancer. Through this work, I aim to broaden my scientific expertise by acquiring numerous technical and transferable skills and to establish myself as an independent researcher in the field of cancer epigenetics.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2016 |
Aliaksandra Radzisheuskaya, Daria Shlyueva, Iris Müller, Kristian Helin Optimizing sgRNA position markedly improves the efficiency of CRISPR/dCas9-mediated transcriptional repression published pages: e141-e141, ISSN: 0305-1048, DOI: 10.1093/nar/gkw583 |
Nucleic Acids Research 44/18 | 2019-04-03 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOVLEUREG" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NOVLEUREG" are provided by the European Opendata Portal: CORDIS opendata.